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Introduction
Epidemiology has contributed to the improvement of clinical prac-
tice in diverse ways. Epidemiological studies have identified most 
major risk factors, especially for cardiovascular disease (CVD). Clin-
ical epidemiology also plays a critical role in the development and 
evaluation of disease screening, diagnosis, and treatment modali-
ties. Disease risk prediction is a relatively new, but very active area 
of research where epidemiologic findings are translated into clini-
cal applications. If we could better predict an individual’s future risk 
for certain diseases, we would then be able to make an efficient and 
personalized treatment plan for the individual. Traditional epidemio-
logic studies measure the strength of association between a risk 
factor and a disease in relative terms such as relative risk and odds 
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ratio. These measures tell us the “relative difference of disease risk” 
between a group of people who are exposed to the risk factor and 
a group who are not exposed. However, with these relative mea-
sures, we cannot estimate an individual’s “absolute” disease risk, 
which is more relevant information when making decision in a cli-
nical setting. Additionally, an individual can be exposed to multiple 
risk factors at various exposure levels, and this makes it difficult to 
estimate an individual’s absolute disease risk. For these reasons, dis-
ease risk prediction models have been developed to assess multiple 
risk factors together and estimate absolute disease risk for each 
individual.
Coronary Heart Disease Prediction Based-on  
Traditional Risk Factors
The predictive capacities among the known major cardiovascular 
risk factors including age, sex, cigarette smoking, high blood pres-
sure, abnormal blood lipids, and diabetes mellitus have been well 
established. Using these major risk factors in a combined manner, 
risk prediction tools have been developed in an effort to assist cli-
nicians in cardiovascular risk assessment and in treatment plann-
ing.1-3) The most widely accepted model is the Framingham Risk Sc-
ore which enrolls traditional risk factors such as age, diabetes, 
smoking, blood pressure, total (or low density lipoprotein) choles-
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terol, and high density lipoprotein-cholesterol (HDL-C) with differ-
ent points (coefficients) in order to assess an individual’s 10-year 
coronary heart disease (CHD) risk.4) The third Report of the Nation-
al Cholesterol Education Program Expert Panel on Detection, Eval-
uation, and Treatment of High Blood Cholesterol in Adults {Adult 
Treatment Panel III (ATP-III)} and many other guidelines for CHD risk 
assessment and prevention are largely based on the Framingham 
equations to predict an individual’s 10-year risk of CHD.5-7) For exam-
ple, according to the ATP-III guidelines, individuals can be catego-
rized into one of 3 risk categories shown in Fig. 1 below.8) For indi-
viduals without established CHD or CHD risk equivalents, a primary 
prevention strategy is determined by using their predicted 10-year 
risk for CHD. Individuals with a 10-year CHD risk >20% are consid-
ered to be at high risk and recommended for immediate use of lipid-
lowering medication. For individuals with moderate risk, the recom-
mendation can be either to start drug therapy or to pursue other 
noninvasive testing for further risk stratification. Low risk individuals 
are typically not recommended for drug therapy, but for lifestyle mo-
dification as appropriate treatment. Studies have shown that the 
CHD risk prediction models, which are based on traditional risk fac-
tors, are considered acceptable in various populations.9) However, 
there is little evidence supporting the idea that existing CHD risk 
prediction tools can improve clinical outcomes,10) and there has 
been much effort to improve the accuracy of the existing CHD risk 
prediction tools.
Coronary Heart Disease Prediction Incorporating 
Newer Biomarkers
A large number of newer biomarkers, which reflect inflammation, 
endothelial function, fibrin formation and fibrinolysis, oxidative 
stress, renal function, ventricular function, and even myocardial cell 
damage have been reported to be associated with cardiovascular 
risk and their predictive values have been studied.11-20) However, only 
a small number of studies have observed a significant improvement 
by adding newer biomarkers in the prediction of CHD risk. Even in 
studies that observed improved predictive power when including 
new biomarkers, the incremental predictive powers were disap-
pointingly small. A multi-marker risk prediction approach, which 
includes several newer biomarkers simultaneously, has been studi-
ed with the goal of improving the accuracy and clinical utility of 
CHD risk prediction.21-24) Some studies have suggested that adding 
several newer biomarkers can substantially improve risk classifica-
tion,23)24) but others have observed only minimal improvement in the 
ability to classify cardiovascular risk by adding multiple biomark-
ers.21)22) Thus, for most of the newer biomarkers, controversy remains 
in the predictability of CHD in the clinical setting. Debate remains 
about the appropriate statistical methods for assessing the incre-
mental value of new biomarkers in the CHD prediction model.
Methods to Assess Clinical Utility  
of New Biomarkers
When a new biomarker is proposed as a risk predictor, the most 
common approach is to compare a new prediction model, including 
the new biomarker, to the existing prediction models that do not in-
clude the new biomarker. A new prediction model should meet at le-
ast 2 criteria in order to replace the existing disease prediction model. 
First, the new model must predict disease risk more accurately than 
existing models. Second, the predicted risks must be sufficiently 
different between the existing and new models to permit changes 
to an individual’s treatment plan.1)25)26) Diverse statistical measures 
should be used to check whether a new prediction model meets th-
ese 2 criteria. McGeechan et al.25) proposed to assess the clinical utili-
ty of new biomarkers or prediction models in 4 summary measures; 
global model fitness, discrimination, calibration, and reclassifica-
tion. “Global model fitness” can be assessed in many ways, among 
which the Akaike Information Criterion and Bayes the Information 
Criterion are the most commonly used measures. These methods are 
useful to not only find the best fit, but also a parsimonious predic-
tion model, because a penalty is paid for increasing the number of 
predictor variables. A model with fewer variables would be preferred 
among the alternative models of equal prediction performance. “Dis-
crimination” is a measure of how well a proposed model separates 
people who develop the disease of interest from people who do not. 
The most common measure of discrimination is the C-statistic {or 
area under the receiver operating characteristic curve, area under 
the curve (AUC)}.27) Incremental discriminative power can be as-
sessed by comparing AUCs between the new model and the existing 
model (Fig. 2). The discriminatory power of disease prediction can 
be also assessed by other indices including, the Yates slope (the dif-
ference between predicted risk between cases and controls; larger 
values indicate better discrimination), the Brier score (the sum of 
High risk:  1) Established CHD, 2) CHD risk equivalents, or  
 3) Multiple risk factors with 10-year CHD risk >20%
Moderate risk: Multiple risk factors with 10-year CHD risk <20%
Low risk: No or one risk factor
Fig. 1. CHD risk classification according to the ATP-III guidelins. Coronary 
heart disease risk equivalents include peripheral arterial disease, abdominal 
aortic aneurysm, and carotid artery disease (i.e., transient ischemic attacks, 
stroke of carotid origin, or >50% obstruction), or diabetes mellitus. Risk fac-
tors include cigarette smoking, hypertension, low HDL-C (<40 mg/dL), fam-
ily history of premature CHD, and age (men ≥45 years; women ≥55 years). 
CHD: coronary heart disease, ATP-III: Adult Treatment Panel III, HDL-C: high 
density lipoprotein-cholesterol.
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squared difference between the observed outcome and fitted prob-
ability; smaller values indicate better fit), and the integrated dis-
crimination improvement.28)29) “Calibration” refer to how close the 
predicted disease risks are to the actual observed risks. Usually, the 
mean predicted risk and observed actual risk are compared accord-
ing to different risk groups (e.g., deciles of risk) (Fig. 3). The signific-
ance of the difference between the predicted and actual risks can 
be tested by the Hosmer and Lemeshow28) chi-square test. “Reclas-
sification” methods have been suggested to provide more clinically 
relevant information by comparing risk classification results from 
a new model to those from an existing model.29) Discrimination indi-
ces do not provide information about the proportion of people 
who are classified into low or high risk groups, but reclassification 
tables can measure the changes in predicted risk categories be-
tween the existing and new models. In addition, the net reclassific-
ation improvement can be calculated for those changes in estimated 
prediction probabilities that imply a change from one category to 
another according to the method described by Pencina et al.29) (Fig. 4). 
In addition to the 4 measures described above, bar graphs and scat-
ter plots may effectively show clinically important information about 
the predictive performance (Fig. 5).2) Lastly calculating the number 
needed to screen (NNS) is another useful way to assess the clinical 
utility of new biomarkers or prediction models. The NNS indicates the 
number of people needed to be tested for the additional biomarker 
to identify the high-risk individual. 
Discrepancy between Epidemiologic Association 
and Clinical Utility
Annually, more than 1000 studies report independent disease risk 
factors or predictors,30) and CHD is among the most frequently 
studied diseases. Numerous biomarkers have been reported to be 
independently associated with CHD risk. However, most clinicians 
do not measure these biomarkers in daily practice, because their cli-
nical utility is limited or uncertain. Newer biomarkers may reflect or 
play a role in inflammation, endothelial dysfunction, fibrin forma-
tion and fibrinolysis, oxidative stress, renal dysfunction, ventricular 
dysfunction, and myocardial cell damage.11-20) Although some of 
these new biomarkers were consistently and independently associ-
ated with CHD risk, the clinical utility of new biomarkers is minimal 
to moderate in the prediction of CHD. A good example is C-reactive 
protein (CRP), an inflammatory marker. CRP level has been studied 
extensively as a potential biomarker that can improve CHD risk pre-
diction,16)22)31-36) but its clinical utility remains controversial. In the 
Women’s Health Study, CRP was strongly associated with CHD risk 
and improved disease prediction.33)36)37) Nested case-control analy-
Fig. 2. Simulated area under the receiver operating characteristic curves 
(AUC or C-statistic). AUC: area under the curve.
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Fig. 3. Simulated calibration charts for 10-year coronary heart disease prediction. A shows good calibration, while B shows poor calibration. CHD: coro-
nary heart disease.
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ses in the Nurses’ Health Study and in the Health Professional Fol-
low-up Study observed that CRP level was independently associated 
with CHD risk in men, but not in women.34) In the British Women’s 
Heart and Health Study, CRP was not significantly associated with 
either CHD or CVD, and it did not improve the identification of risk in 
women.35) In the Women’s Health Study, CRP levels ≥3 mg/L were 
significantly associated with CVD risk, independent of metabolic 
abnormalities.33) However, those relationships were not observed in 
the nested case-control studies performed in the Nurses’ Health 
Study.34) In the Women’s Health Initiative datasets, CRP was not sig-
nificantly associated with CHD after adjustment for traditional risk 
factors (p=0.767), and did not improve discriminative power of CHD 
prediction (p=0.296).2) According to a systematic review by Shah et 
al.,38) CRP level is consistently associated with CHD risk, but CRP 
testing provides only limited information for risk prediction than 
tests of association alone might suggest. In summary, there is strong 
evidence that CRP level is associated with CHD risk, but its clinical 
utility as a routine screening test is still uncertain because moderate 
improvement in risk stratification has been observed only in parts 
of the studies.39) Researchers examined other biomarkers including 
lipoprotein-associated phospholipase A2, N-terminal prohormone of 
brain natriuretic peptide (NT-proBNP), troponins, myeloperoxidase, 
fibrinogen, fibrin, D-dimer, macrophage chemoatractant protein-1, 
adiponenctin, cystatin C, and interleukin-6.26) Many of these biomark-
ers were consistently associated with CHD incidence or mortality but 
their practical value in the CHD prediction was not evident. 
Even with the multiple biomarker approach, we have not yet fo-
und a reliable set of biomarkers that improves CHD risk stratifica-
tion sufficiently. When compared to the risk prediction using con-
ventional risk factors, adding multiple biomarkers did not significant-
ly improve discrimination index in the Framingham Heart Study21) 
and the Cardiovascular Health Study.40) In the nested case-control 
study from the Women’s Health Initiative, adding the 5 most signi-
ficant biomarkers moderately improved discrimination between cas-
es and controls (C-statistic increased by 0.016, p=0.027).2) On the 
other hand, the Uppsala Longitudinal Study reported that a set of 
biomarkers (CRP, NT-proBNP, troponin I, and cystatin C) markedly 
increased C-statistic by 0.11 (p<0.001).24) However the Uppsala study 
can be distinguished from others in several aspects; their study 
population was older (≥75 years), the primary outcome was not CHD 
Fig. 5. Simulated scatter plot showing the performance of two prediction 
models. Both X and Y axes are in logarithmic scales. Red dots indicate peo-
ple who developed CHD, and blacks dots indicate people who did not. Blue 
lines indicate cut-off points determining risk categories. CHD: coronary 
heart disease.
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Fig. 4. Simulated reclassification tables comparing two prediction models. Net reclassification index (NRI)=Proportion of cases who were reclassified into 
higher category (11.7+1.7+1.0=14.4%)-Proportion of cases who were reclassified into lower category (0.7+0.3+0.7=1.7%)+Proportion of controls who 
were reclassified into lower category (0.8+0.3+0.5=1.6%)-Proportion of controls who were reclassified into higher category (3.3+0.8+0.5=4.6%)=9.8%.
In cases
Risk category with old model 
(not including biomarker)
Risk category with new model (including biomarker)
Total
Low risk Intermediate risk High risk
Low risk (%) 230 (76.7) 35 (11.7) 5 (1.7) 270 (90.0)
Intermediate risk (%) 2 (0.7) 15 (5.0) 3 (1.0) 20 (6.7)
High risk (%) 1 (0.3) 2 (0.7) 7 (2.3) 10 (3.3)
Total (%) 233 (77.7) 52 (17.3) 15 (5.0) 300 (100)
In controls
Risk category with old model 
(not including biomarker)
Risk category with new model (including biomarker)
Total
Low risk Intermediate risk High risk
Low risk (%) 525 (87.5) 20 (3.3) 5 (0.8) 550 (91.7)
Intermediate risk (%) 5 (0.8) 22 (3.7) 3 (0.5) 30 (5.0)
High risk (%) 2 (0.3) 3 (0.5) 15 (2.5) 20 (3.3)
Total (%) 532 (88.7) 45 (7.5) 23 (3.8) 600 (100)
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incidence but mortality, and the biomarker panel included cystatin C, 
troponins, and NT-proBNP reflect existing cardiac or renal damage. 
The United States Preventive Services Task Force systematically 
reviewed the 9 most commonly studied emerging risk factors {CRP 
level, coronary artery calcium, lipoprotein(a), homocysteine, leuko-
cyte count, fasting glucose level, periodontal disease, ankle-brachial 
index, and carotid inima-media thickness} for the prediction of CHD, 
and evaluated the clinical usefulness of these 9 risk factors.41) They 
concluded that the current evidence does not support the routine 
use of any of the 9 risk factors for improved CHD risk stratification. 
In addition, the task force discussed CRP as being the best candi-
date for use in screening, but it remains uncertain as to whether a ch-
ange in CRP will lead to the primary prevention of CHD.39)
Clinical Utility Issues in Korea
Cardiovascular risk prediction tools have also been suggested for 
the Korean population42)43) but they are of limited clinical use for a 
few reasons. First, the clinical utility of newer biomarkers in CHD 
prediction can be population-specific. When we add a new biomark-
er measurement to existing risk predictors, the added biomarker 
should be able to improve the predicted risk enough to change an 
individual’s treatment plan. This issue is of concern within the scope 
of clinically relevant risk reclassification, and is critically important in 
Korea. Clinically significant reclassification is not frequent in Korea. 
Because CHD incidence is relatively low in Korea, most individuals 
fall into the low-risk group when their CHD risk is assessed. Even if 
a new biomarker significantly improves the prediction accuracy, 
changes in the predicted CHD risk are mostly within the same risk 
category. This makes it difficult to identify high-risk individuals by 
measuring additional biomarkers. 
Clinically useful biomarkers in a certain population can be of little 
use in a different population.
Moreover, clinical practice guidelines for risk assessment and the 
prevention of CHD, which are customized for the Korean popula-
tion, are not available. Thus, it is impractical to evaluate whether a 
new biomarker could change an individual’s treatment plan or not. 
In addition to the clinically relevant reclassification, the cost-effec-
tiveness of the testing of new biomarkers needs to be determined. 
In order to determine the clinical utility of new biomarkers in the 
prediction of CHD, we need a wealth of epidemiological and clinical 
data that are more relevant to the Korean population. Further stud-
ies should be finely designed to answer the full range of issues and 
criteria relating to utilization on a clinical level.
In summary, biomarkers that are currently available provide only 
a minimal to moderate improvement in the prediction of CHD risk. 
Some newer biomarkers may have the potential to improve CHD 
risk assessment and may contribute to the personalized primary 
prevention of CHD, however newer biomarkers should be assessed 
more extensively for their predictive power and clinical utility, es-
pecially in the Korean population. 
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